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Available online 2 March 2018Objective. In clinical practise, prognostication of endometrial cancer is based on clinicopathological risk fac-
tors. The use of immunohistochemistry-based markers as prognostic tools is generally not recommended and
a systematic analysis of their utility as a panel is lacking.We evaluatedwhether an immunohistochemicalmarker
panel could reliably assess endometrioid endometrial cancer (EEC) outcome independent of clinicopathological
information.
Methods. A cohort of 306 EEC specimenswas profiled using tissuemicroarray (TMA). Cost- and time-efficient
immunohistochemical analysis of well-established tissue biomarkers (ER, PR, HER2, Ki-67, MLH1 and p53) and
two new biomarkers (L1CAM and ASRGL1) was carried out. Statistical modelling with embedded variable selec-
tion was applied on the staining results to identifyminimal prognostic panels withmaximal prognostic accuracy
without compromising generalizability.
Results. A panel including p53 and ASRGL1 immunohistochemistry was identified as the most accurate pre-
dictor of relapse-free and disease-specific survival. Within this panel, patients were allocated into high- (5.9%),
intermediate- (29.5%) and low- (64.6%) risk groups where high-risk patients had a 30-fold risk (P b 0.001) of
dying of EEC compared to the low-risk group.
Conclusions. P53 and ASRGL1 immunoprofiling stratifies EEC patients into three risk groupswith significantly
different outcomes. This simple and easily applicable panel could provide a useful tool in EEC risk stratification
and guiding the allocation of treatment modalities.
© 2018 Elsevier Inc. All rights reserved.Keywords:
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Endometrial cancer (EC) is themost common gynaecologic cancer in
developed countries. Approximately 80% of EC cases are of
endometrioid (EEC) type. The majority of EEC cases are detected at an
Table 1
Clinicopathological characteristics of the presented 306 EEC cases (A) and their association
with risk assessing immunoprofile (B, n= 305).
A B
Low-riskb Intermediate-riskc High-riskd
Agea 66 (59–73) 66 (59–73) 66 (58–74) 70 (65–76)
Figo stage I 247 (80.7%) 171 (69.5%) 64 (26.0%) 11 (4.5%)
II 9 (2.9%) 7 (77.8%) 1 (11.1%) 1 (11.1%)
III 42 (13.7%) 16 (38.1%) 23 (54.8%) 3 (7.1%)
IV 8 (2.6%) 3 (37.5%) 2 (25.0%) 3 (37.5%)
Grade 1 166 (54.2%) 131 (78.9%) 32 (19.3%) 3 (1.8%)
2 87 (28.4%) 52 (59.8%) 30 (34.5%) 5 (5.7%)
3 53 (17.3%) 14 (26.9%) 28 (53.8%) 10 (19.2%)
MI b50% 206 (67.3%) 144 (70.2%) 52 (25.4%) 9 (4.4%)
≥50% 100 (32.7%) 53 (53.0%) 38 (38.0%) 9 (9.0%)
LVI No 203 (66.3%) 131 (64.9%) 59 (29.2%) 12 (5.9%)
Yes 37 (12.1%) 15 (40.5%) 18 (48.6%) 4 (10.8%)
Missing 66 (21.6%)
N(%)
a Median (IQR).
b Low-risk: p53 wild-type, ASRGL1 N 75%.
c Intermediate-risk: p53 wild-type, ASRGL1 ≤ 75% or p53 aberrant and ASRGL1 N 75%.
d High-risk: p53 aberrant, ASRGL1 ≤ 75%.
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favourable. Still, over 10% of early stage EEC cancers relapse [1,2]. Cur-
rently, we are unable to assess accurately the outcome of early EEC pa-
tients. This either leads to unnecessary follow-up for the majority of
patients, or to suboptimal treatment of the patients who eventually suf-
fer from relapse. Following the principles of disease stratification as a
step towards personalized treatment of EEC, biomarkers are needed to
identify patient subgroups that would most benefit from additional ad-
juvant therapy. A number of tissue biomarkers have been introduced for
EEC prognostication [3,4]. However, the integration of biomarkers into
clinical guidelines has been slow.
In this study, our aim was to identify a prognostic panel of bio-
markers based solely on immunohistochemical stainings, accompanied
by sophisticated statistical modelling. More specifically, we wanted to
test whether prognostication of EEC would be feasible using only
tissue-derived parameters. For this purpose, we chose a set of well-
established tissue markers that are known to have a prognostic value
in EEC. These include ER and PR, whose prognostic role has been con-
firmed in several studies [5,6]. P53 was included, as its independent
prognostic role in EC has repeatedly been shown [7–9]. Additional bio-
markers included Ki-67, MLH1 and HER-2 [10–12]. Finally, two recently
characterized promising biomarkers were included: L1-cell adhesion
molecule (L1CAM) and ʟ-asparaginase like 1 (ASRGL1). The prognostic
value of L1CAM has been shown in various settings, both in type I and
II EC [2,13–18] and it has attained an established role in EC biomarker
panels both in retrospective and prospective studies. ASRGL1 is a
novel biomarker candidate, which we recently demonstrated to have
an independent prognostic value in two independent EEC cohorts [19]
and the prognostic role of ASRGL1 was confirmed in a recent study
[20]. Additionally, the ASRGL1 gene has been identified as an important
hub genewhen comparingmost differentially expressed genes between
EEC and non-endometrioid carcinoma [21].
Although disease stratification by integration of different “omics”
data is a promising future approach [22], both technological and finan-
cial constraints limit thesemethods to a few centres. For routine clinical
diagnostics, there is still a dire need for robust, low-cost and widely
applicable prognostic tools. In this study, sophisticated statistical
modelling techniqueswere used to identifyminimal panels of immuno-
histochemical markers that are capable of providing maximally predic-
tive and practical tools for comprehensive prediction and modelling of
EEC patient characteristics. Ourmain aimwas to construct two separate
panels; one useful in a pre-operative setting, which would predict clin-
icopathological risk-factors and aid in surgical treatment planning, and
another to be used in a postoperative setting to identify patients who
are at risk of disease relapse or death due to the disease.
2. Material and methods
2.1. Patient characteristics
During the years 2001–2007, 327 women with endometrial cancer
were operated in Turku University Hospital. Both full patient records
and paraffin-embedded material were available. From this cohort, we
excluded 14 patientswith a non-endometrioid ormixed-type histology,
four patients who received any form of pre-operative treatment and
three due to unsatisfactory tissue material. The remaining 306 EEC pa-
tients were included in this study. All the patients were restaged (AA,
JH) based on patient record information in accordance with the FIGO
2009 staging guidelines [23]. The study was approved by the Ethical
Committee of the Southwestern Finland Hospital District and the Finn-
ish National Authority for Medicolegal Affairs.
The histopathology of each tumor was re-classified by two expert
gynaecopathologists (LT, OC) according to the FIGO guidelines [23,24].
Demographic, clinical, and pathologic information and follow-up data
for relapse or death was obtained from the hospital records. The pa-
tients were followed until September 2014 or death. The survival datawere obtained from the hospital records and the Population Registry,
and the cause of death from Statistics Finland. Disease relapse and
death due to disease were registered as the end-point events for post-
operative modelling. No patients were lost to follow-up.
The clinical and pathologic features of the 306 EEC patients included
in this study are summarized in Table 1A. All patients were surgically
treated; 74% underwent surgical staging, of which 58.2% underwent
pelvic and 15.4% both pelvic and para-aortic lymphadenectomy. Adju-
vant therapy was primarily given according to the hospital guidelines,
provided that there was no patient-related impairment.
During a median follow-up of 7.2 years (range 0.15–13.02), 40
(13.1%) of the patients experienced a relapse. The majority of these
(87.5%) were distant relapses. During a median 7.4 years follow-up,
10.1% died of EEC.
2.2. Tissue microarrays (TMAs) and immunohistochemistry (IHC)
Generation of TMAs, basic IHC techniques, and slide scanning were
performed as previously described [19,25] at the Swedish Science for
Life Laboratory (SciLifeLab) Tissue Profiling Facility at Uppsala
University (Sweden), in accordance with the standards used in The
Human Protein Atlas project (www.proteinatlas.org) [26]. The study
was performed in accordance with recommended biomarker reporting
guidelines (REMARK). Detailed information on the antibodies used in
this study is presented in supplementary data.
The immunohistochemically stained slides were scanned and inde-
pendently evaluated by two pathologists (OC and JH). Both tissue
cores for each case were analysed and an average was determined and
used for further analysis. If staining result was assessed as a continuous
variable, an average of the two cores was calculated. In cases with dis-
crepancies in evaluation, the slides were re-evaluated until an agree-
ment was reached.
Immunoreactivity for ER, PR, ASRGL1 and Ki-67 was quantitatively
scored based on positive staining of tumor cells. The frequency was
assessed semi-quantitatively in 6 classes (0%; 1–10%; 11–25%;
25–50%; 51–75% and N75% thresholds). P53 staining was considered
aberrant if cancerous cells were completely negative, or if moderate-
to-strong nuclear staining was present in over 75% of the tumor cells.
HER-2 staining was considered positive if membranous staining in
N10%of the tumor cells of strong intensitywere present.MLH1was con-
sidered negative if there was no evident staining in the cancer cells but
stromal cells showed positive staining. L1CAMwas considered negative
if b10% of tumor cells were positive, as on the threshold if approxi-
mately 10% of cells were negative, and as positive if N10% were positive
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tumor specimens served as controls.
For prognostic modelling, ER, PR and ASRGL1 were classified using
conventional frequency thresholds in order to facilitate the clinical use
of the potential immunopanel. The threshold approachwas also applied
tominimize potentialmethodological issues, such as the reproducibility
of intensity values across laboratories, and thereby to increase the com-
parability and generalizability of the models to different clinical setups
[27].2.3. Statistical modelling
The prognostic variables for the predictive modelling included
age, p53 status, HER-2 overexpression, MLH1 positivity, L1CAM sta-
tus, and the frequencies of PR, ER, Ki67 and ASRGL1. The immuno-
staining frequencies were systematically tested with varying cut-
offs, and incorporated as binary indicators in the regression model.
In post-operative modelling, radiotherapy (pelvic and/or brachy-
therapy), chemotherapy and operational treatment were included
to adjust for potential confounding effects. Potential confounder co-
efficients were omitted from the final model. LASSO logistic regres-
sion [28] and its Cox variant [29] were utilized for predictive
modelling based on the pre- and post-operative panels, respectively.
A sequence of lambda LASSO parameters was tested using 10-fold
cross-validation (CV) to optimize ROC-AUC and c-index metrics in
the logistic and Cox regression, respectively. The final models were
fitted using conservative lambda value within one standard error of
the CV-optimum, which resulted in the proposed optimal set of pre-
dictive markers as well as their specific thresholds by the feature se-
lection embedded in LASSO regression covering all the potential
marker candidates. The P-values for the identified pre-operative
panels were computed using the Fisher's exact test. Statistical testing
of the post-operative risk groups was performed using conventional
Cox proportional hazards. All statistical tests were two-sided.
The heatmap clustering of the immunohistological variables was
conducted using complete linkage with the Euclidean distance. The
cut-offs were derived from the optimized LASSO models. The R soft-
ware (version 3.3.1) was utilized in all the statistical analyses ex-
tended by R-packages glmnet (version 2.0–5) and hamlet (version
0.9.5) (both publicly available in the CRAN repository). The R-code
for reproducing data analysis and modelling is provided in the Sup-
plementary Material.2.4. ASRGL1 gene expression
To correlate ASRGL1 gene expression with outcome, endometrial
cancer patient samples (n = 541) from The Cancer Genome Atlas
(TCGA) project were used. Both transcriptomics data (RNA-Seq) and
clinical information was collected from the Genomic Data Commons
(GDC) (https://gdc-portal.nci.nih.gov/). Transcriptomics data was re-
trieved as FPKM (fragments per kilobase of exon per million mapped
reads) values from tumor tissues representing endometrial cancer and
clinical data included overall survival time for corresponding patients.
In the analysis, we excluded genes with low expression, i.e., those
with a median expression among samples less than one. A cut-off
value of 1 FPKM was used as a detection limit.
Based on the ASRGL1 FPKM values, patients were classified into two
groups The prognosis of each group of patients was examined by
Kaplan-Meier survival estimators, and the survival outcomes of the
two groups were compared by log-rank tests. To choose the optimal
FPKM cut-off for stratifying the patients into two different prognostic
groups, the most significant P-value within the 20th to 80th percentile
was used and the cut -off for low and high ASRGL1 expression groups
was set at 55.3 FPKM.3. Results
Two different risk stratification strategies were assessed; one for
post-operative risk stratification and the other for pre-operative risk as-
sessment. The post-operative prognostic model identified the combina-
tion of p53 and ASRGL1 (cut-off 75%) staining as the best predictor of
both disease-free survival (DFS) and disease-specific survival (DSS).
Based on the model-identified prognostic panel, the patients were
grouped into three risk categories: low-risk (p53 wild type, ASRGL1
N 75%), intermediate-risk (p53wild type, ASRGL1 ≤ 75%or p53 aberrant,
ASRGL1 N 75%) and high-risk (p53 aberrant, ASRGL1 ≤ 75%). Of all 306
EEC cases, 64.6% belonged to the low-risk group, 29.5% to the
intermediate-risk group and 5.9% to the high-risk group. The survival
rates of these categories are presented in Fig. 1A. In the high-risk
group, 61.1% (11/18) patients died from disease, compared to 15.6%
(14/90) in the intermediate-risk group and 3.0% (6/197) of patients in
the low-risk group. Patient records of the low-risk patients that died
of disease were revisited. Of these six patients, three had advanced,
stage III or IV disease. Further, a patient died of an EEC treatment related
cause while another underwent only vaginal hysterectomy due to uter-
ine prolapse, relapsed and died of disease after 5.5 years of EEC despite
compensatory radiation therapy. For the single remaining case no risk
factor could be identified.
When compared to the low-risk group patients, patients considered
to have an intermediate-risk disease had a 5.8-fold risk [HR 5.85(CI
2.22–15.33), P b 0.001] whereas the high-risk disease cases had a 30-
fold risk [HR 30.1(CI 10.93–83.14), P b 0.001] of dying from disease
[HR 30.1(CI 10.93–83.14), P b 0.001, Cox regression model]. The
association between the risk classes, determined by ASRGL1 and p53
expression, and clinicopathological factors is presented in Table 1B.
Stage (I-II/III-IV), grade and age where entered in a Cox regression
model (backward stepwise likelihood ratio) together with risk-class
data. Stage and risk-class where included in the final model where
stage had a HR of 5.31 (CI 2.53–11.10, P b 0.001) and intermediate-
risk and high-risk classes a HR of 3.93 (CI 1.46–10.57, P b 0.007) and
HR 20.38 (CI 7.19–57.72, P b 0.001), respectively.
Based on the statistical modelling, cut-off values were set for each
marker, and these values were used to categorize the EECs into groups.
The cut-offs and numbers of cases within each category are shown in
Table 2. The IHC results were clustered together with the clinicopatho-
logical variables as a dendrogram and a heatmapwas produced to illus-
trate the relationship between the different markers (Fig. 2), with the
visualizedmarker thresholds chosen according to the identified optimal
models. As shown in the heatmap, hormonal receptors (ER, PR) were
correlated with ASRGL1 (pairwise Spearman rho correlations: ER and
PR: 0.6527; ASRGL1 and ER: 0.4218; and ASRGL1 and PR: 0.5339, with
all pairwise correlations highly statistically significant P b 0.001). The
cases with sparse or negative staining for these biomarkers were clus-
tered together. Also the clinical end-points, death from disease and dis-
ease relapse, as well as cases with high-grade and advanced disease
were classified into the ER/PR/ASRGL1 negative clusters indicating a
clinical significance of the these markers.
In the current EEC cohort, a statistically significant co-expression
was found between the p53 status and L1CAM stainings (Fisher's
exact test, P b 0.001, Fig. 2). Of the p53 aberrant cases, 13 (36.1%)
were L1CAM positive, and of the 27 L1CAM positive cases 13 (48.1%)
were p53 aberrant. Additionally, 8 (47.1%) of the 17 cases with high-
risk immunoprofile were L1CAM positive. The correlation between the
L1CAM and p53 expression and the disease-specific and recurrence-
free survival is presented in Fig. 1B. According to our analyses, p53 aber-
rant tumours had a significantly adverse prognosis regardless of the
L1CAM status. However, the overlap of the twomarkers was significant.
Moreover, we searched for a potential pre-operative panel for deep
myometrial invasion (MI), presence of lymphovascular invasion (LVI)
and advanced, FIGO stage III-IV disease. Three panels consisting of ER,
PR and/or ASRGL1 with different threshold values were identified
Fig. 1. Kaplan-Meier estimates of the effect of marker combinations on disease specific survival and disease free survival: (A) p53 and ASRGL1 and (B) p53 and L1CAM expression.WT=
wild type, AB = aberrant p53 expression. *** P b 0.001.
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predictor of MI. For LVI, ER (cut-off 1%) combined with PR (cut-off
25%) provided the best panel for prediction. A large majority, 149
(93%), of the hormone receptor positive cases did not present with
LVI. Of the LVI-positive EECs, 26 (70%) were negative for ER and/or PR.
Finally, the combination of PR (cut-off 10%) and ASRGL1 (cut-offs 25%
and 75%)was the best predictor for advanceddisease (FIGO stage III-IV).
Finally, to further validate our results also on the mRNA level in an
independent cohort, we utilized gene expression data from the publicly
available TCGA data set [30]. To study the association between ASRGL1
expression and outcome for patients with endometrial cancer, ASRGL1
gene expression (mRNA) was assessed from 541 tumours and the cut
-off for low and high ASRGL1 expression groups was set at 55.3 FPKM.
A Kaplan-Meier analysis based on this cut-off showed that patients
with tumours showing low expression of ASRGL1 have a significantly
(P b 0.001) shorter overall survival rate as compared to patients with
high ASRGL1 expression (Fig. 3).
4. Discussion
There is a profound need for improved risk assessment methods for
patients with EEC. The existing risk stratifications guiding surgical treat-
ment and adjuvant therapy allocation consist of clinicopathologicalvariables. These variables i.e. stage, histology, grade, myometrial inva-
sion and lymphovascular invasion often associate with disease progres-
sion and survival, but may not truly reflect tumor biology [31].
Moreover, the reproducibility of FIGO grading has been unsatisfactory
[11,24], and significant discrepancy rates have been reported [1].
Tumor grade can be assessed on pre-operative samples, but the consis-
tency between pre- and post-operative findings can bemodest [32]. The
assessment of MI and LVI can only be done on the surgical specimen,
and both of these events are dependent on the representative sampling
of tumor specimen and prone to errors such as pseudoinvasion [33].
None of the current risk classifications provide high accuracy in stratify-
ing the risk of recurrence or nodalmetastasis [34]. Additionally, discrep-
ancies between the pre- and postoperative risk assessment have been
reported [35], emphasizing the need for improved diagnostic tools to
be developed using robust statistical methods.
We show that a panel of two IHC markers only, p53 and ASRGL1,
could be a useful tool in risk assessment of EEC. With p53 and ASRGL1
immunohistochemistry, patients can be categorized into three risk clas-
ses in each of which the outcome is significantly different (Fig. 1). Pa-
tients with aberrant p53 and low ASRGL1 (≤75%) expression are at the
highest risk for relapse or disease-related death. The inclusion of p53
in the panel is not surprising as its prognostic role in EEC has been
shown earlier [7–9]. Although aberrant p53 is typically associated
Table 2
The distribution of immunohistochemical staining results.
ER N (%)
b1% 39 (12.7%)
1–50% 79 (25.8%)
N50% 188 (61.4%)
PR⁎
b10% 64 (21.0%)
10–25% 18 (5.9%)
N25% 223 (73.1%)
ASRGL1⁎
b25% 40 (13.1%)
25–75% 49 (16.0%)
N75% 216 (70.8%)
p53
Wild type 269 (87.9%)
Aberrant 37 (12.1%)
L1CAM⁎
Negative 278 (91.1%)
Threshold 7 (2.3%)
Positive 20 (6.6%)
ERBB2†
Normal 293 (98.7%)
Overexpressed 4 (1.3%)
MLH1
Negative 91 (29.7%)
Positive 215 (70.3%)
Ki-67
b25% 137 (44.8%)
25–75% 139 (45.4%)
N75% 30 (9.8%)
The missing values are due to the loss of both TMA duplicate
cores in the corresponding stainings.
⁎ n= 305.
† n= 297.
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characterized by mutant p53 [22]. Somewhat surprisingly, L1CAM was
not included in the prognostic panel, despite studies showing its prog-
nostic value in EC [14,17,36]. Themost likely explanation for this obser-
vation is, that L1CAM expression has been found to correlate with
aberrant p53 and to be related to non-endometrioid morphology
[14,17,36]. The penalized regression methodology aims to find a mini-
mal set of explaining variables thus leading to the inclusion of only a sin-
gle variable of a set of highly correlated markers, and eludes markersFig. 2. Heatmap of immunohistochemical staining data and clinicopathological factors. The d
Euclidean distance.that do not add to the prognostic value of the panel. Thus, in the present
study the LASSO regression model p53 was superior to L1CAM. A small
proportion of the cases in this study presented a endometrioid histology
butwere, however, both p53 aberrant and L1CAMpositive indicating an
immunohistochemical expression typical to serous carcinoma.
Distinguishing EEC from serous carcinoma from H&E slides is often
rather straightforward, however, the morphological subclassification
might fail to identify a proportion of non-endometrioid cases [37] and
the reproducibility of histiotype is problematic even in themost experi-
enced hands [38].
ASRGL1 is a novel biomarker candidate, which has demonstrated
to have an independent prognostic value in EEC [19,20]. In this study,
we show in an independent cohort that in addition to reduced
ASRGL1 protein expression, also low ASRGL1 gene expression is
associated with adverse prognosis, which further strengthens the
prognostic role of ASRGL1 expression in endometrial cancer cells.
Additional confirmatory evidence for the role of ASRGL1 in EC has
come from a recent gene regulatory network analysis, which identi-
fied ASRGL1 as an important hub gene when comparing most differ-
entially expressed genes between EEC and non-endometrioid
carcinoma [21]. Although ASRGL1 was not associated with EEC spe-
cific survival in the aforementioned study, the results emphasize
the importance of ASRGL1 in EEC.
ASRGL1 is demonstrated to degrade both ʟ-asparagine and
isoaspartyl peptides in vitro [39] indicating that the loss of ASRGL1
could lead to elevated asparagine levels. In a recent study on breast can-
cer, the authors show that asparagine synthetase expression in a pri-
mary tumor correlated with later metastatic relapse suggesting that
the bioavailability of asparagine strongly influencesmetastatic potential
[40]. Further on, altering asparagine availability had an influence on in-
vasive potential, thought to relate to the effect on proteins that promote
the epithelial-to-mesenchymal transition [40]. The authors also
analysed the TCGA Pan-Cancer expression data of asparaginase synthe-
tase (ASNS) and showed that endometrial cancer survival was better in
the ASNS low -group, further emphasizing the importance of asparagine
in endometrial cancer [40]. Themetastatic potential of ASRGL1 depleted
EC is supported by the finding made by Fonnes et al., who showed that
77% of metastatic lymph nodes were ASRGL1 negative and that many
ASRGL1 high primary tumours presented with ASRGL1 low metastasis
[20].
The ʟ-Asparaginase has long been used to treat acute lymphoblastic
leukaemia but has not yet been as successful in solid tumours. Still, high
asparagine levels in EC – either due tohigh asparagine synthetase or low
asparaginase levels – could potentially be targeted with ʟ-asparaginase
treatment.endrogram on top was computed using complete linkage clustering, coupled with the
Table 3
Pre-operative panel identified using penalized logistic LASSO regression. Grey-colored cells were used for predicting higher risk category for computing the positive predictive values
(PPV) and negative predictive values (NPV).
A) Myometrium invasion 
noisavnimuirtemoymfohtpeD
ER Frequency <50% >50% 
>50% 148 (78.7%) 40 (21.3%) 
<50% 58 (49.2%) 60 (50.8%) 
Cells indicate number of samples (proportion). 
P < 0.001, Fisher's exact test; PPV: 50.9%, NPV: 78.7%. 
B) Lymphovascular invasion*
noisavniralucsavohpmyL *
seYoN
PR Frequency > 25% < 25% > 25% < 25% 
ER Freq. >1% 149 (72.3%) 34 (16.5%) 11 (5.3%) 12 (5.8%) 
ER Freq. <1% 8 (24.2%) 11 (33.3%) 2 (6.1%) 12 (36.4%) 
*67 missing values (28%). 
P < 0.001, Fisher's exact test; PPV: 32.9%, NPV: 93.1%. 
C) Stage I/II versus III/IV 
 Stage*
VI/IIIII/I
PR Frequency >10% <10% >10% <10% 
ASRGL1 >75% 184 (85.2) 11 (5.1%) 16 (7.4%) 5 (2.3%) 
ASRGL1 25–75% 27 (49.1%) 14 (25.5%) 8 (14.5%) 6 (10.9%) 
ASRGL1 <25% 2 (6.1%) 16 (48.5%) 4 (12.1%) 11 (33.3%) 
*2 missing values (0.7%). 
P < 0.001, Fisher's exact test; PPV: 39.6%, NPV: 88.4%. 
178 J. Huvila et al. / Gynecologic Oncology 149 (2018) 173–180The model predicting deep MI, LVI and advanced disease suggested
that ER, PR and ASRGL1 could be usefulmarkers in such risk assessment.
No single model or panel to predict the high-risk cases could be identi-
fied, which suggest that different mechanisms may lead to similar pat-
terns of disease spread and invasion. Further complexity stems from
the uncertainty in the evaluation of these clinicopathological variables.
However, our results further confirm the role of ER, PR and ASRGL1 in
preoperative risk assessment of EEC.
There is currently a relatively large variation in the cut-off values used
to determine immunohistochemical staining results in EEC and one of
our aims was to search for clinically relevant cut-off values for the
immunomarkers. Our data suggested that the currently used definition
of aberrant p53 expression and ASRGL1 positivity in over 75% of cancer
cells are good predictors of survival in EEC. The widely studied bio-
markers in ER and PR still lack established cut-off values, and in many
cases the used cut-off values are the same used in breast cancer diagnos-
tics, typically N10% and N1%. In our study, no single cut-off could be deter-
mined and further work is needed to determine optimal cut-offs.
The Cancer Genome Atlas (TCGA) data highlighted the endometrial
cancer heterogeneity, especially in high-grade carcinomas in EC
[22,41]. Based on the TCGA data, a new classification tool, ProMisE,
was developed, using IHC determination of DNA mismatch repair
genes and p53, and an analysis of POLEmutation profile [42] to identify
those risk groups presented in the TCGA study. The immunopaneldeveloped in the present study shares some elements (p53, MLH1)
with the ProMisE classification tool. Ourmain aimwas not to categorize
patients but rather to evaluate the prognostic capacity of an
immunopanel in risk assessment of EC, therefore complementing the
prior results from TCGA.
The strengths of our study include a well-described, unselected pa-
tient cohort, with complete clinical follow-up data. We used universal,
easily assessable and usable immunohistochemical stainings, which
have good repeatability across different laboratories. Our studymaterial
was selected to consist only of morphologically defined EEC, however
the immunohistological results indicate that a portion of these could
represent serous- or serous like carcinomas. As stated above, subclassi-
fication based on purely morphological features might fail to identify a
proportion of non-endometrioid cases highlighting the need for bio-
markers. Another major strength of the current study is the systematic
statistical modelling and variable selection technique applied in both
the pre- and post-operative panels, which not only identified the max-
imally predictive panels of markers, but also recognized their clinically
relevant cut-off thresholds without á priori assumptions. Oneweakness
of this study is that the presented immunopanel remains yet to be val-
idated in a separate cohort. Additionally, 215 of the extended cohort
with 306 patients were readily included in the original ASRGL1 study
[19], and there is a possibility of slight overfitting of ASRGL1 in this ma-
terial due to re-modelling parts of the data.
Fig. 3.Kaplan-Meier plot basedASRGL1mRNA expression shows that the patient group (n
= 306) with relative low (b55.3 FPKM) expression levels of ASRGL1 has a decreased
overall survival rate compared to the patient group (n= 235) with a relative high level
(N55.3 FPKM) of ASRGL1 expression.
179J. Huvila et al. / Gynecologic Oncology 149 (2018) 173–180Our results emphasize the prognostic role of p53 expression in EEC.
Additionally, our results support the independent prognostic role of the
novel biomarker ASRGL1 and highlight its prognostic value as compared
to several established biomarkers. Further studies are needed to confirm
the prognostic immunopanel presented in this study and to verify the
optimal thresholds for EEC prognosis, preferably in a prospective
setting. Also, translational studies are required to understand the
biological implications between reduced ASRGL1 expression and EEC
aggressiveness.
In conclusion, a simple and affordable immunohistochemistry panel
consisting of p53 and ASRGL1 provides important information for EEC
risk stratification. Such stratification could help to modify follow-up
strategies and reduce unnecessary visits and health-care costs without
compromising outcome results.
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